Urolithin derivatives and therapeutic uses

A compound of Formula (I):

• wherein
• Y1 and Y2 are each alkyl;
• or taken together with the carbon to which they are bonded combine to form an unsubstituted or substituted spiro cycloalkyl;
• R1, R4, R5, and R8 are independently selected from —H and halogen;
• R2 and R7 are independently selected from —H, —OH, —OAc, —NH2, halogen, —CN, —CF3, —CO2H, —NO2, —NHAc, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkylamino, alkyl-R9, alkenyl-R9, alkynyl-R9, —OR10, —NHR10, —NR11C(O)R12, —C(O)NR11R12, and —NR11SO2R12;
• R3 and R6 are independently selected from alkyl and cycloalkyl;
• each occurrence of R9 is independently selected from OH, NH2, O-alkyl, O-alkyl-O-alkyl, alkylamino, NHC(O)-alkyl, N(CH3)C(O)-alkyl, NHSO2-alkyl, N(CH3)SO2-alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
• R10 is selected from alkyl, hydroxyalkyl, aminoalkyl, alkyl-O-alkyl, alkyl-O-alkyl-OH, alkyl-O-alkyl-O-alkyl, alkenyl, alkynyl, heteroarylalkyl, heteroarylalkyl, alkyl-cycloalkyl, alkyl-heterocycloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, SO3H, SO2-alkyl, and SO2-haloalkyl;
• each occurrence of R11 is selected from H and alkyl;
• and
• each occurrence of R12 is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, O-alkyl, aminoalkyl, heteroarylalkyl, heteroarylalkyl, alkyl-cycloalkyl, and alkyl-heterocycloalkyl;
• provided that when R1, R4, R5, and R8 are each —H, R2 and R7 are each —OH, and R3 and R6 are each CH3, then Y1 and Y2 are not each -Me or are not taken together with the carbon to which they are bonded to form an unsubstituted spiro cyclobutyl;
• or a pharmaceutically acceptable salt thereof.